France: Updated pricing framework for orphan drugs in France
Following publication of the “accord cadre” between the CEPS and the LEEM at the end of last year, both parties have now signed an amendment aimed at better defining the pricing framework for orphan drugs. This will play a crucial part of any pricing negotiation between manufacturers and the CEPS, influencing pricing models and access agreements, and potentially have a knock-on effect on international reference pricing for orphan drugs in the future. It is hoped this will ensure faster access to innovative drugs in areas where no treatment is currently available. In this update, Yasmina Zegaoui, Senior Consultant outlines the key changes.
View the amendment in full here
Lightning Health can support you to navigate these complexities and to ensure robust value demonstration across healthcare systems. Contact us to discuss how we can support your European launch and patient access strategy.
Article published 19 April 2022.